Amarillo Biosciences Enters Into a License and Supply Agreement With CytoPharm for Low Dose Oral Interferon Use in Animal Diseases in China and Taiwan

Published: Mar 25, 2008

AMARILLO, TX and TAIPEI, TAIWAN--(Marketwire - March 25, 2008) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has entered into a license and supply agreement (Agreement) with CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company and specialty Clinical Research Organization in Taiwan specializing in pharmacogenomics.

Back to news